PROM1 and neoplasm: Interestingly, preclinical studies investigating the role of anti-AC133 NIR-PIT showed not only a significant reduction in tumour growth but also a delayed CSC-driven tumour initiation when subcutaneous CD133-positive GMB xenografts were treated with NIR-light (Jing et al., 2016).